Related Experiment Video
Updated: Nov 16, 2025
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.1K
A Candidate Prognostic Biomarker Complement Factor I Promotes Malignant Progression in Glioma
Xiaomin Cai1, Wenjin Qiu2, Mengshu Qian3
1Department of Neurosurgery, The 904th Hospital of Joint Logistic Support Force of People's Liberation Army (PLA), Clinical Medical College of Anhui Medical University, Wuxi, China.
Frontiers in Cell and Developmental Biology
|February 22, 2021
Summary
Complement factor I (CFI) is overexpressed in aggressive glioma, correlating with poor patient outcomes. Inhibiting CFI shows potential for treating this deadly brain tumor.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Glioma is a prevalent and aggressive primary central nervous system (CNS) tumor with high mortality.
- Identifying novel prognostic biomarkers and therapeutic targets for glioma is critical.
Purpose of the Study:
- To investigate the prognostic significance of complement factor I (CFI) in glioma.
- To elucidate the functional role of CFI in glioma progression.
Main Methods:
- Analysis of CFI expression and patient survival data from TCGA and GTEx databases.
- Correlation of CFI expression with clinicopathological features using Cox regression in the CGGA database.
- In vitro and in vivo functional assays to determine CFI's role in glioma cell behavior.
Main Results:
- CFI is overexpressed in glioma tissues and associated with poor prognosis in TCGA and CGGA datasets.
- CFI serves as an independent prognostic factor for glioma.
- CFI knockdown inhibits glioma cell growth, while its overexpression promotes proliferation, migration, and invasion.
Conclusions:
- Complement factor I (CFI) is a potential prognostic biomarker for glioma.
- CFI drives glioma's malignant progression and represents a therapeutic target.
